1Le Chevalier T,Brisgand D,Douillard JY,et al.Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small cell lung cancer:Results of a European multicenter trial including 612 patients[J].J Clin Oncol,1994,12:360-367.
2Crino L,Scagliotti GV,Ricci S,et al.Gemcitabine and cisplatin versus mitomycin,ifosfamide,and cisplatin in advanced non-small cell lung cancer:A randomized phase Ⅲ study of the ltalian Lung Cancer Project[J].J Clin Oncol,1999,17:3522-3530.
3Socinski MA,Schell MJ,Peterman A,et al.Phase Ⅲ trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage Ⅲ B/IV non-small cell lung cancer[J].J Clin Oncol,2002,20:1335-1343.
4Smith IE,O'Brien ME,Talbot DC,et al.Duration of chemotherapy in advanced non-small cell lung cancer:A randomized trial of three versus six courses of mitomycin,vinblastine and cisplatin[J].J Clin Oncol,2001,19:1336-1343.
5Fossella FV,DeVore R,Kerr RN,et al.Randomized phase Ⅲ trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens:The TAX 320 Non-Small Cell Lung Cancer Study Group[J].J Clin Oncol,2000,18:2354-2362.
6Shepherd FA,Dancey J,Ramlau R,et al.Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinumbased chemotherapy[J].J Clin Oncol,2000,18:2095-2103.
7Dancey J,Shepherd F,Ramlau R,et al.Quality of life (QOL) assessment in a randomized study of taxotere (TAX) versus best supportive care (BSC) in non-small cell lung cancer (NSCLC) patients (pts) previously treated with platinumbased chemotherapy[J].Proc Am Soc Clin Oncol,1999 (abstr 1896),18:491.
8Fukuoka M,Yano S,Giaccone G,et al.Multi-institutional randomized phase Ⅱ trial of Gefitinib for reviously treated patients with advanced non-small cell lung cancer[J].J Clin Oncol,2003,21:2237-2246.
9Kris MG,Natale RB,Herbst RS,et al.A phase Ⅱ trial of ZD 1839 (Iressa) in advanced non-small cell lung cancer (NSCLC) patients who had failed platinum-and docetaxed-based regiment (IDEAL2)[J].Proc Am Soc Clin Oncol,2002 (abstr 1166),21:292a.
10Giaccone G,Johnson DH,Manegold C,et al.A phase Ⅲ clinical trial of ZD 1839 (lressa) in combination with gemcitabine and cisplatin in chemotherapy-native patients with advanced non-small cell lung cancer (INTACT 1)[J].European Society for Medical Oncology Congress,2002 (abstr 1166),October 18-22,Nice,France.
7Kennedy B J.Thesnail's pace of lung carcinoma chemotheraphy[J].Cancer,1998,82(5):801-803
8Morikawak,HosokawaM,Hamaddj,etal.Possible participation of tumoricidal macrophage in the therapeutic effect of bieomycinona transplantable rat fibro sarcoma[J].CancerRes,1996,46
9Rixe O,Ortuzar W,Alvarez M,et,al.Oxaliplatin,tetralatin,cisplatin,and carboplatin:spectrum of activity in drug resistant cell lines and in the cell lines of the nation cancer institute's anticancer drug screen panel[J].Biochem Pharmacol,1996,52(12):1855-1858
